Clinical trial
Multicentre, Open-Label, Single-Arm, 52-Week, Ph3b Study to Evaluate the Efficacy and Safety Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Moderate-Severe Systemic Lupus Erythematosus (SLE)
NCT07751848 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicentre, Open-Label, Single-Arm, 52-Week, Ph3b Study to Evaluate the Efficacy and Safety Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Moderate-Severe Systemic Lupus Erythematosus (SLE)
- Lead sponsor
- AstraZeneca
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- August 31, 2026
- Completion date
- August 30, 2028
- Enrollment
- 417 (estimated)
- Sites
- 71
Conditions
As the registry lists them; a condition with its own page is linked.